Why Hims & Hers Health, Inc. (HIMS) Skyrocketed This Week

We recently published a list of These 10 Stocks Moved the Market This Week, Here’s Why. In this article, we are going to take a look at where Hims & Hers Health, Inc. (NYSE:HIMS) stands against other stocks that moved the market this week.

The stock market edged lower week-on-week, as cautious investors repositioned their portfolios ahead of the United States and China’s high-stakes negotiations on trade policies that have for months dented global economies.

On a week-on-week basis, the Dow Jones was down by 0.16 percent, the S&P 500 dropped 0.47 percent, while the Nasdaq dipped by 0.27 percent.

Beyond the major indices, 10 companies bucked a wider market decline, with gains skyrocketing in just a week’s trading.

In this article, we name the 10 top-performing companies this week and the primary reasons that bolstered their gains.

To come up with the list, we considered only the stocks with a $2-billion market capitalization and $5-million trading volume.

The stocks were chosen based on the highest percentage increase in closing prices on May 9 as against their prices a week earlier, or on May 2.

Hims & Hers Health, Inc. (NYSE:HIMS)

Hims & Hers Health saw its share prices jump by 27.29 percent week-on-week, ending Friday’s trading at $51.96 versus the $40.82 close a week earlier, as investors cheered its impressive earnings performance and expectations of more clinched partnerships for the rest of the year.

In its latest earnings release, Hims & Hers Health, Inc. (NYSE:HIMS) said that its net income expanded by 346 percent to $49.5 million from the $11.1 million registered in the same period last year, while revenues soared by 111 percent to $586 million from $278.2 million year-on-year.

The company said that its strong performance underpinned its updated 2025 guidance, with full-year revenues expected to settle between $2.3 billion and $2.4 billion, and the second quarter to end at $530 million to $550 million.

In recent news, Hims & Hers Health, Inc. (NYSE:HIMS) clinched a long-term deal with Novo Nordisk to jointly market the latter’s blockbuster weight loss drug, Wegovy, which now allows users to access NovoCare Pharmacy directly through its platform.

Apart from Novo Nordisk, the company said it is set to ink more deals with other companies soon.

Overall, HIMS ranks 9th on our list of stocks that moved the market this week. While we acknowledge the potential of HIMS as an investment, our conviction lies in the belief that AI stocks hold greater promise for delivering higher returns and doing so within a shorter time frame. There is an AI stock that went up since the beginning of 2025, while popular AI stocks lost around 25%. If you are looking for an AI stock that is more promising than HIMS but that trades at less than 5 times its earnings, check out our report about this cheapest AI stock.

READ NEXT: 20 Best AI Stocks To Buy Now and 30 Best Stocks to Buy Now According to Billionaires.

Disclosure: None. This article is originally published at Insider Monkey.